Literature DB >> 22924434

Progress in the development and application of small molecule inhibitors of bromodomain-acetyl-lysine interactions.

David S Hewings1, Timothy P C Rooney, Laura E Jennings, Duncan A Hay, Christopher J Schofield, Paul E Brennan, Stefan Knapp, Stuart J Conway.   

Abstract

Bromodomains, protein modules that recognize and bind to acetylated lysine, are emerging as important components of cellular machinery. These acetyl-lysine (KAc) "reader" domains are part of the write-read-erase concept that has been linked with the transfer of epigenetic information. By reading KAc marks on histones, bromodomains mediate protein-protein interactions between a diverse array of partners. There has been intense activity in developing potent and selective small molecule probes that disrupt the interaction between a given bromodomain and KAc. Rapid success has been achieved with the BET family of bromodomains, and a number of potent and selective probes have been reported. These compounds have enabled linking of the BET bromodomains with diseases, including cancer and inflammation, suggesting that bromodomains are druggable targets. Herein, we review the biology of the bromodomains and discuss the SAR for the existing small molecule probes. The biology that has been enabled by these compounds is summarized.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22924434     DOI: 10.1021/jm300915b

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  48 in total

1.  Structure of the Brd4 ET domain bound to a C-terminal motif from γ-retroviral integrases reveals a conserved mechanism of interaction.

Authors:  Brandon L Crowe; Ross C Larue; Chunhua Yuan; Sonja Hess; Mamuka Kvaratskhelia; Mark P Foster
Journal:  Proc Natl Acad Sci U S A       Date:  2016-02-08       Impact factor: 11.205

Review 2.  Small-molecule inhibitors of the Myc oncoprotein.

Authors:  Steven Fletcher; Edward V Prochownik
Journal:  Biochim Biophys Acta       Date:  2014-03-19

3.  1,3-Dimethyl Benzimidazolones Are Potent, Selective Inhibitors of the BRPF1 Bromodomain.

Authors:  Emmanuel H Demont; Paul Bamborough; Chun-Wa Chung; Peter D Craggs; David Fallon; Laurie J Gordon; Paola Grandi; Clare I Hobbs; Jameed Hussain; Emma J Jones; Armelle Le Gall; Anne-Marie Michon; Darren J Mitchell; Rab K Prinjha; Andy D Roberts; Robert J Sheppard; Robert J Watson
Journal:  ACS Med Chem Lett       Date:  2014-09-10       Impact factor: 4.345

4.  Structure-Guided Design of IACS-9571, a Selective High-Affinity Dual TRIM24-BRPF1 Bromodomain Inhibitor.

Authors:  Wylie S Palmer; Guillaume Poncet-Montange; Gang Liu; Alessia Petrocchi; Naphtali Reyna; Govindan Subramanian; Jay Theroff; Anne Yau; Maria Kost-Alimova; Jennifer P Bardenhagen; Elisabetta Leo; Hannah E Shepard; Trang N Tieu; Xi Shi; Yanai Zhan; Shuping Zhao; Michelle C Barton; Giulio Draetta; Carlo Toniatti; Philip Jones; Mary Geck Do; Jannik N Andersen
Journal:  J Med Chem       Date:  2015-07-06       Impact factor: 7.446

Review 5.  Epigenetic pathway targets for the treatment of disease: accelerating progress in the development of pharmacological tools: IUPHAR Review 11.

Authors:  David F Tough; Huw D Lewis; Inmaculada Rioja; Matthew J Lindon; Rab K Prinjha
Journal:  Br J Pharmacol       Date:  2014-11       Impact factor: 8.739

6.  [Epigenetic modifications in autoimmune diseases].

Authors:  A Ramming; J H W Distler; G Schett; S Gay; A Jüngel
Journal:  Z Rheumatol       Date:  2014-09       Impact factor: 1.372

7.  Discovery and lead identification of quinazoline-based BRD4 inhibitors.

Authors:  Shyh-Ming Yang; Daniel J Urban; Makoto Yoshioka; Jeffrey W Strovel; Steven Fletcher; Amy Q Wang; Xin Xu; Pranav Shah; Xin Hu; Matthew D Hall; Ajit Jadhav; David J Maloney
Journal:  Bioorg Med Chem Lett       Date:  2018-08-31       Impact factor: 2.823

Review 8.  Bromodomain and extra-terminal (BET) family proteins: New therapeutic targets in major diseases.

Authors:  Balasundaram Padmanabhan; Shruti Mathur; Ramu Manjula; Shailesh Tripathi
Journal:  J Biosci       Date:  2016-06       Impact factor: 1.826

9.  Discovery of I-BRD9, a Selective Cell Active Chemical Probe for Bromodomain Containing Protein 9 Inhibition.

Authors:  Natalie H Theodoulou; Paul Bamborough; Andrew J Bannister; Isabelle Becher; Rino A Bit; Ka Hing Che; Chun-wa Chung; Antje Dittmann; Gerard Drewes; David H Drewry; Laurie Gordon; Paola Grandi; Melanie Leveridge; Matthew Lindon; Anne-Marie Michon; Judit Molnar; Samuel C Robson; Nicholas C O Tomkinson; Tony Kouzarides; Rab K Prinjha; Philip G Humphreys
Journal:  J Med Chem       Date:  2015-04-30       Impact factor: 7.446

10.  Fragment-Based Discovery of a Selective and Cell-Active Benzodiazepinone CBP/EP300 Bromodomain Inhibitor (CPI-637).

Authors:  Alexander M Taylor; Alexandre Côté; Michael C Hewitt; Richard Pastor; Yves Leblanc; Christopher G Nasveschuk; F Anthony Romero; Terry D Crawford; Nico Cantone; Hariharan Jayaram; Jeremy Setser; Jeremy Murray; Maureen H Beresini; Gladys de Leon Boenig; Zhongguo Chen; Andrew R Conery; Richard T Cummings; Leslie A Dakin; E Megan Flynn; Oscar W Huang; Susan Kaufman; Patricia J Keller; James R Kiefer; Tommy Lai; Yingjie Li; Jiangpeng Liao; Wenfeng Liu; Henry Lu; Eneida Pardo; Vickie Tsui; Jian Wang; Yongyun Wang; Zhaowu Xu; Fen Yan; Dong Yu; Laura Zawadzke; Xiaoqin Zhu; Xiaoyu Zhu; Robert J Sims; Andrea G Cochran; Steve Bellon; James E Audia; Steven Magnuson; Brian K Albrecht
Journal:  ACS Med Chem Lett       Date:  2016-03-15       Impact factor: 4.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.